Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2− advanced breast cancer: results from BOLERO-2
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Cancer"
DOI: 10.1038/bjc.2017.25
Abstract: Background:The current analysis was performed to evaluate the impact of PIK3CA hotspot mutations on everolimus efficacy in BOLERO-2 participants, using cell-free DNA (cfDNA) from plasma samples collected at the time of patient randomisation.Methods:PIK3CA H1047R, E545K,… read more here.
Keywords: dna; everolimus efficacy; free dna; cell free ... See more keywords
Biomarkers of everolimus efficacy in breast cancer therapy
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552211073673
Abstract: Objective Everolimus is an inhibitor of serine/ threonine kinase mTOR. The drug is approved for the treatment of metastatic ER positive, HER2 negative breast cancers and benefits a subset of patients with these breast cancers… read more here.
Keywords: breast cancer; breast; efficacy breast; everolimus efficacy ... See more keywords